US 10,889,865 B2
Thyroid tumors identified
Thomas J. Fahey, III, Larchmont, NY (US); Nimmi Kapoor, Orange, CA (US); and Theresa Scognamiglio, Brooklyn, NY (US)
Assigned to Cornell University, Ithaca, NY (US)
Filed by Cornell University, Ithaca, NY (US)
Filed on Feb. 23, 2017, as Appl. No. 15/440,489.
Application 15/440,489 is a continuation of application No. 14/087,812, filed on Nov. 22, 2013, granted, now 9,587,279.
Application 14/087,812 is a continuation of application No. 13/063,429, abandoned, previously published as PCT/US2009/005091, filed on Sep. 11, 2009.
Claims priority of provisional application 61/191,845, filed on Sep. 12, 2008.
Claims priority of provisional application 61/207,812, filed on Feb. 17, 2009.
Prior Publication US 2017/0166980 A1, Jun. 15, 2017
Int. Cl. C12Q 1/6883 (2018.01); C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 1/6883 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method comprising:
measuring levels of RNA expressed by genes consisting of DPP4, MATN2, PROS1, RXRG, TIMP1, SERPINA1, ChGn, and SLC4A4 in a test thyroid tissue or thyroid cell sample from one or more patients by microarray analysis and/or quantitative polymerase chain reaction using primers or probes specific for DPP4, MATN2, PROS1, RXRG, TIMP1, SERPINA1, ChGn, and SLC4A4; and
treating the one or more patients that have a test thyroid tissue or thyroid cell sample exhibiting at least a 2.5-fold increase in each measured RNA expression level of DPP4, SERPINA1, PROS1, RXRG, and TIMP1, and at least a 2.5-fold decrease in each measured expression level of MATN2, ChGn, and SLC4A4 RNA, compared to respective RNA expression levels of DPP4, MATN2, PROS1, RXRG, TIMP1, SERPINA1, ChGn, and SLC4A4 genes in a benign thyroid standard sample, where the treatment comprises thyroidectomy, central neck dissection, or radioactive iodine therapy.